{"id":"W1775596629","doi":"10.1182/blood.v118.21.606.606","title":"Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; McMaster University Medical Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Medicine; Imatinib; Internal medicine; Imatinib mesylate; Clinical endpoint; Myeloid leukemia; Oncology; Gastroenterology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002285984,0.0003325754,0.0007423289,0.0001731834,0.000151514,0.00048086,0.0003419447,0.0005178763,0.001544343],"category_scores_gemma":[0.001204271,0.0001790616,0.0008204584,0.0001838699,0.0003833707,0.0005030006,0.0003317268,0.001098234,0.0002223173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004183665,"about_ca_system_score_gemma":0.0004589488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002829983,"about_ca_topic_score_gemma":0.0006650292,"domain_scores_codex":[0.9995046,0.0002738826,0.00003795196,0.00007713553,0.00005287471,0.00005348421],"domain_scores_gemma":[0.998875,0.0004232879,0.0003526433,0.00005466465,0.00004324763,0.0002511338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.828729,0.01641158,0.07250415,0.000526799,0.001264003,0.0001784275,0.0001468498,0.001628484,0.01756207,0.0001310413,0.001087442,0.05983013],"study_design_scores_gemma":[0.1584139,0.6429337,0.1858877,0.00005154532,0.001377183,0.0006178201,0.0001012811,0.002433683,0.005942936,0.0001972436,0.002003567,0.00003936416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986635,0.0004569498,0.0001106715,0.00004119903,0.00001097869,0.0001969537,0.0001902673,0.000009123713,0.0003203375],"genre_scores_gemma":[0.9986424,0.0001724681,0.0002053801,0.00009483382,0.00002454472,0.0001989669,0.0003818327,0.000002740783,0.0002768116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002285984,"threshold_uncertainty_score":0.01208961,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01716219875039676,"score_gpt":0.2530342717225034,"score_spread":0.2358720729721067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}